Loading viewer...
investor_presentation
Format: PDF investor_presentation
Mural Oncology plc presents its protein engineering capabilities and engineered cytokine programs, including nemvaleukin alfa for cancer immunotherapy. The presentation covers clinical development timelines, potential therapeutic applications across multiple tumor types, and combination therapy strategies within the ARTISTRY development program.
investor_presentation
24 Pages
Novolipetsk Steel
Karyopharm Therapeutics Investor Presentation — August 2020
investor_presentationinvestor_presentation
17 Pages
Karyopharm Therapeutics Inc.